X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Inversago will further strengthen Nordisk's clinical pipeline in obesity, diabetes and other metabolic diseases by including its lead development asset INV-202, an oral CB1 inverse agonist, currently in a phase 2 trial for diabetic kidney disease.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,075.0 million Upfront Cash: $1,075.0 million
Deal Type: Acquisition August 10, 2023
Details:
INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Proceeds from financing will be used to move lead program, INV-202, into a Phase 2 in Diabetic Kidney Disease in Q4 2022. Additionally, the funds will accelerate other programs currently in pre-clinical development, while establishing its leadership in CB1 blockers.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 17, 2022
Details:
INV-202 showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.
Lead Product(s): INV-202
Therapeutic Area: Nephrology Product Name: INV-202
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome, non-alcoholic steatohepatitis, type 1 diabetes, diabetic nephropathy and chronic kidney diseases, among others.
Lead Product(s): INV-202
Therapeutic Area: Genetic Disease Product Name: INV-202
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
As a new generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi syndrome (PWS), NASH, type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
Lead Product(s): INV-202
Therapeutic Area: Genetic Disease Product Name: INV-202
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and non-alcoholic steatohepatitis (NASH).
Lead Product(s): INV-101
Therapeutic Area: Genetic Disease Product Name: INV-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Inversago will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.
Lead Product(s): INV-101
Therapeutic Area: Genetic Disease Product Name: INV-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
